BURLINGTON, Mass., March 28, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at Needham & Company’s 16th Annual Healthcare Conference on Tuesday, April 4, 2017 at 3:40 p.m. EDT at the Westin Grand Central Hotel in New York.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 syoung@flexiontherapeutics.com
